Literature DB >> 8756624

Cyclin-binding motifs are essential for the function of p21CIP1.

J Chen1, P Saha, S Kornbluth, B D Dynlacht, A Dutta.   

Abstract

The cyclin-dependent kinase (Cdk) inhibitor p21 is induced by the tumor suppressor p53 and is required for the G1-S block in cells with DNA damage. We report that there are two copies of a cyclin-binding motif in p21, Cy1 and Cy2, which interact with the cyclins independently of Cdk2. The cyclin-binding motifs of p21 are required for optimum inhibition of cyclin-Cdk kinases in vitro and for growth suppression in vivo. Peptides containing only the Cy1 or Cy2 motif partially inhibit cyclin-Cdk kinase activity in vitro and DNA replication in Xenopus egg extracts. A monoclonal antibody which recognizes the Cy1 site of p21 specifically disrupts the association of p21 with cyclin E-Cdk2 and with cyclin D1-Cdk4 in cell extracts. Taken together, these observations suggest that the cyclin-binding motif of p21 is important for kinase inhibition and for formation of p21-cyclin-Cdk complexes in the cell. Finally, we show that the cyclin-Cdk complex is partially active if associated with only the cyclin-binding motif of p21, providing an explanation for how p21 is found associated with active cyclin-Cdk complexes in vivo. The Cy sequences may be general motifs used by Cdk inhibitors or substrates to interact with the cyclin in a cyclin-Cdk complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756624      PMCID: PMC231467          DOI: 10.1128/MCB.16.9.4673

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  In vitro cell cycle arrest induced by using artificial DNA templates.

Authors:  S Kornbluth; C Smythe; J W Newport
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

2.  Analysis of wild-type and mutant p21WAF-1 gene activities.

Authors:  J Lin; C Reichner; X Wu; A J Levine
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase.

Authors:  E M Lees; E Harlow
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint.

Authors:  W Krek; G Xu; D M Livingston
Journal:  Cell       Date:  1995-12-29       Impact factor: 41.582

6.  Inhibition of DNA replication factor RPA by p53.

Authors:  A Dutta; J M Ruppert; J C Aster; E Winchester
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

7.  Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21.

Authors:  Z Q Pan; J T Reardon; L Li; H Flores-Rozas; R Legerski; A Sancar; J Hurwitz
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

8.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

9.  Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.

Authors:  I T Chen; M Akamatsu; M L Smith; F D Lung; D Duba; P P Roller; A J Fornace; P M O'Connor
Journal:  Oncogene       Date:  1996-02-01       Impact factor: 9.867

10.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  108 in total

1.  Overproduction of human Myt1 kinase induces a G2 cell cycle delay by interfering with the intracellular trafficking of Cdc2-cyclin B1 complexes.

Authors:  F Liu; C Rothblum-Oviatt; C E Ryan; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  Differential control of transcription by DNA-bound cyclins.

Authors:  T Y Kim; W G Kaelin
Journal:  Mol Biol Cell       Date:  2001-07       Impact factor: 4.138

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.

Authors:  X Lin; P Nelson; I H Gelman
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein.

Authors:  S Shintani; H Ohyama; X Zhang; J McBride; K Matsuo; T Tsuji; M G Hu; G Hu; Y Kohno; M Lerman; R Todd; D T Wong
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

6.  Roughex mediates G(1) arrest through a physical association with cyclin A.

Authors:  S N Avedisov; I Krasnoselskaya; M Mortin; B J Thomas
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

9.  P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes.

Authors:  Tapan K Bagui; Subhra Mohapatra; Eric Haura; W J Pledger
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.

Authors:  E Castaño; Y Kleyner; B D Dynlacht
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.